Market Brief — September 2, 2026
Risk-on · Supportive. 23 Buy / 124 Hold / 35 Sell across 182 names. Top conviction: INTU.
Market Brief — September 2, 2026
Auto-generated by FilingSight from live FRED macro data and the latest SEC-derived company reports.
Macro regime
Risk-on · Supportive.
| Gauge | Status | Detail |
|---|---|---|
| Growth & Recession Gauge | Mixed / caution | Mixed / caution. Payrolls softening. |
| Inflation Regime | Moderating | Moderating. Headline CPI +3.3% YoY, core +2.5% YoY; 5Y breakeven 2.37%. |
| Financial Conditions | Neutral | Neutral. VIX 14.92, BAA-10Y credit spread 1.59pp. |
| Policy Stance | Near neutral | Near neutral. Fed funds 3.63%, real rate 1.16%. |
Rates & inflation
Fed funds 3.63%, headline CPI YoY 3.3%, VIX 14.9, yield curve upward-sloping.
Coverage breadth
Across 182 tracked names: 23 bullish, 124 neutral, 35 bearish outlook.
Highest-conviction bullish names:
- INTU (Intuit Inc.) — Buy, composite score 35, confidence 83%.
- CME (CME Group Inc.) — Buy, composite score 33, confidence 81%.
- ALL (Allstate Corp.) — Buy, composite score 32, confidence 81%.
- CF (CF Industries) — Buy, composite score 32, confidence 82%.
Most bearish names:
- TSLA (Tesla Inc.) — Sell, score -40.
- ON (ON Semiconductor Corp.) — Sell, score -40.
- MAR (Marriott International) — Sell, score -32.
What to watch
With the Fed on hold at 3.63% and core disinflation intact, the supportive macro backdrop keeps dips shallow, but the breadth skew toward Hold (124) versus Buy (23) argues for selective accumulation rather than broad beta chasing. Watch INTU and CME as high-quality compounders benefiting from durable software and exchange pricing power, while ALL and CF offer defensive earnings insulation if the VIX mean-reverts above 15. The upward-sloping curve and stable CPI at 3.3% validate a carry-over-equity stance, yet the thin buy list signals that incremental longs should be concentrated in names with visible catalysts, not index-level exposure.
FilingSight is informational and educational only, generated from public data. Not investment advice.